Benzinga | Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals

Market Overview

0.0000 0 (%)

Data as of Aug 19, 2019

Prev. Close
Price Open
Volume 0
Day's Range -
52 Wk Range -
50 Day Moving Avg.
PE Ratio
Shares Outstanding
Market Cap

Trade PTIE stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Pain Therapeutics Reports Name Change To Cassava Sciences, Will Change Ticker To 'SAVA' Benzinga NewsdeskWed, 27 Mar 2019 08:30:51 -0400
Pain Therapeutics Q4 EPS $(0.04) Up From $(0.37) YoY Benzinga NewsdeskMon, 25 Mar 2019 08:33:13 -0400
Watching Stocks With Alzheimer's Treatment Candidates: Merck, Roche, AbbVie, Neurotrope, AC Immune, Denali, INmune Bio, BioXcel Therapeutics, Intra-Cellular, Anavex, Pain Therapeutics, Grifols Benzinga NewsdeskThu, 21 Mar 2019 07:37:57 -0400
Pain Therapeutics 13G Shows New 6.4% Stake From Hudson Bay Capital Management Benzinga NewsdeskTue, 05 Feb 2019 14:14:34 -0400
Pain Therapeutics shares are trading lower after the company said it is no closer to FDA approval for REMOXY following a recent meeting with the FDA. Benzinga NewsdeskTue, 05 Feb 2019 09:47:59 -0400
Pain Therapeutics Announces Feedback From Recent Meeting With FDA On REMOXY To Resolve Disagreements With FDA; FDA Denied Making Errors Or Material Mistakes During Advisory Committee Meeting, Co. Says It Is No Closer To Product Approval Benzinga NewsdeskTue, 05 Feb 2019 09:07:46 -0400
Pain Therapeutics Announces Academic Collaboration with The University of Texas at Austin Benzinga NewsdeskThu, 17 Jan 2019 10:08:14 -0400
Pain Therapeutics Awarded $1.5M Research Grant By National Institutes Of Health Benzinga NewsdeskWed, 16 Jan 2019 10:04:10 -0400
The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results Shanthi RexalineSun, 23 Dec 2018 11:37:02 -0400
Pain Therapeutics S-1 Shows Registration For ~9.127M Common Share Issuable Upon Exercise Of Warrants Offering Via Selling Shareholders Benzinga NewsdeskTue, 18 Dec 2018 18:33:12 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Pain Therapeutics Announces Name Change to Cassava Sciences, Inc. Globe NewswireMar 27, 2019
Pain Therapeutics Reports 2018 Financial Results and Corporate Update Globe NewswireMar 25, 2019
Pain Therapeutics Announces Feedback from Recent Meeting with FDA on REMOXY Globe NewswireFeb 05, 2019
Pain Therapeutics Announces Academic Collaboration with The University of Texas at Austin Globe NewswireJan 17, 2019
Pain Therapeutics Awarded $1.5 Million Research Grant by National Institutes of Health Globe NewswireJan 16, 2019
Pain Therapeutics Announces Two New Peer-Reviewed Publications for REMOXY Globe NewswireJan 07, 2019
Pain Therapeutics Announces Filing of Registration Statement on SEC Form S-1 Globe NewswireDec 18, 2018
Pain Therapeutics Announces Initiation of a Phase II Study in Alzheimer's Disease Globe NewswireDec 06, 2018
Pain Therapeutics Appeals FDA Decision on REMOXY Globe NewswireNov 12, 2018
Pain Therapeutics Reports Third Quarter 2018 Financial Results Globe NewswireOct 29, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Pain Therapeutics now Cassava Sciences Seeking AlphaMar 27, 2019
Purdue Pharma settles opioid case in OK for $270M Seeking AlphaMar 26, 2019
Healthcare stocks stand out among premarket losers Seeking AlphaMar 25, 2019
Pain Therapeutics reports Q4 results Seeking AlphaMar 25, 2019
Painkiller stocks in the red on possible Purdue bankruptcy Seeking AlphaMar 04, 2019
FDA finalizes guidance for developing meds for opioid dependence Seeking AlphaFeb 06, 2019
Trevena leads healthcare gainers; OPKO Health and Pain Therapeutics among losers Seeking AlphaFeb 05, 2019
Pain Therapeutics down 23% premarket on lack of progress with Remoxy NDA refiling Seeking AlphaFeb 05, 2019
OPK and CHD among premarket losers Seeking AlphaFeb 05, 2019
Study links opioid prescriptions to marketing spend Seeking AlphaJan 18, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Will PTIE be a Portfolio Killer in August?

Zacks Investment Research is releasing its prediction for PTIE based on the 1-3 month trading system that more than doubles the S&P 500. This report is free today for Benzinga readers. Click here - the PTIE analysis is free »

Powered by StockSnips

78.22% Positive

Fastest Market News Application
You'll Hear It First On Pro

Login Register for Trial

Brokerage Center

Compare All Online Brokerages